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ABSTRACT: Microvesicles (MVs) and exosomes comprise a
class of cell-secreted particles termed extracellular vesicles
(EVs). These cargo-holding vesicles mediate cell-to-cell
communication and have recently been implicated in neurodegenerative diseases such as Alzheimer’s disease (AD). The
two types of EVs are distinguished by the mechanism of cell
release and their size, with the smaller exosomes and the larger
MVs ranging from 30 to 100 nm and 100 nm to 1 μm in
diameter, respectively. MV numbers are increased in AD and
appear to interact with amyloid-β peptide (Aβ), the primary
protein component of the neuritic plaques in the AD brain. Because microglial cells play such an important role in AD-linked
neuroinﬂammation, we sought to characterize MVs shed from microglial cells, better understand MV interactions with Aβ, and
determine whether internalized Aβ may be incorporated into secreted MVs. Multiple strategies were used to characterize MVs
shed from BV-2 microglia after ATP stimulation. Confocal images of isolated MVs bound to ﬂuorescently labeled annexin-V via
externalized phosphatidylserine revealed a polydisperse population of small spherical structures. Dynamic light scattering
measurements yielded MV diameters ranging from 150 to 600 nm. Electron microscopy of resin-embedded MVs cut into thin
slices showed well-deﬁned uranyl acetate-stained ring-like structures in a similar diameter range. The use of a ﬂuorescently
labeled membrane insertion probe, NBD C6−HPC, eﬀectively tracked MVs in binding experiments, and an Aβ ELISA conﬁrmed
a strong interaction between MVs and Aβ protoﬁbrils but not Aβ monomers. Despite the lesser monomer interaction, MVs had
an inhibitory eﬀect on monomer aggregation. Primary microglia rapidly internalized Aβ protoﬁbrils, and subsequent stimulation
of the microglia with ATP resulted in the release of MVs containing the internalized Aβ protoﬁbrils. The role of MVs in
neurodegeneration and inﬂammation is an emerging area, and further knowledge of MV interaction with Aβ may shed light on
extracellular spread and inﬂuence on neurotoxicity and neuroinﬂammation.
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1. INTRODUCTION
Emerging evidence strongly suggests that extracellular vesicles
(EVs), including exosomes and microvesicles (MVs), are an
operational component of innate immune physiology with an
important role in mediating neuroinﬂammatory and neurodegenerative disease processes such as Alzheimer’s disease
(AD).1−3 Both MVs and exosomes are released from numerous
cell types but diﬀer in cargo, mechanism of secretion, and
size.4−6 MVs (100−1000 nm diameter) are much larger than
exosomes (30−100 nm)2, thus allowing separation of the two
vesicle types by diﬀerential centrifugation. Inwardly budding
exosomes, as part of a secreted multivesicular body, fuse with
the plasma membrane and are released.2 Outwardly budding
MVs are shed from cells after the bud pinches oﬀ from the cell
surface. A signiﬁcant accumulation of literature shows the
involvement of exosomes in many physiological and disease
processes, including neurodegeneration.1,7 MVs are not as wellresearched, but they have also been recognized as transporters
of various biomolecules, mediators of neuron−glia signaling,
and a secretory pathway for cytokines such as interleukin-1β
(IL-1β).7−9
© 2018 American Chemical Society

Size and mechanism of cell release are important distinguishing features of MVs and exosomes. Additional characteristics of
MVs include ﬂipping of phosphatidylserine (PS) from the
inside wall of the plasma membrane to the outer leaﬂet.
Accordingly, MVs have a high aﬃnity for annexin-V.10
Although both MVs and larger apoptotic bodies display
externalized PS, MV formation and budding (blebbing) is not
linked to cell death, further distinguishing the two vesicle
types.11 A primary stimulus of MV formation and shedding is
through activation of microglial P2X7 receptors with exogenous
ATP. This pathway likely involves Na+/Ca2+ inﬂux, K+ eﬄux,
and membrane depolarization.11,12 Acid sphingomyelinase
activity also plays a role in ATP-stimulated MV release and
the protein is present in shed MVs.13 It has been demonstrated
that numerous proteins including signaling components can be
found in shed MVs, including essential parts of the NLRP3
inﬂammasome.9,11 The link between these diﬀusible vesicular
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Figure 1. Microvesicles are shed from microglia after stimulation with ATP. (A) General procedure for isolation of microvesicles from microglial
cells. Conﬂuent microglia in T75 or T150 cell culture ﬂasks were washed with PBS and treated with aCSF containing 1 mM ATP or 100 μM BzATP
for 10 min. The conditioned solution was collected and centrifuged at 2000g for 20 min. The supernatant was then centrifuged at 12 000−15 000g
for 40 min. The resulting pellet was washed several times and reconstituted for further studies. (B) Protein content was determined by BCA assay as
described in the Methods in reconstituted MVs obtained from microglia that were exposed to aCSF alone (aCSF-MVs) or aCSF containing 1 mM
ATP (ATP-MVs). Data represent the average ± standard error for protein concentration measurements of 4 separate MV preparations (**p < 0.01).

Figure 2. Microglial-derived microvesicles bind ﬂuorescently labeled annexin-V. MVs obtained from BV-2 microglia were incubated with AF488annexin-V conjugate as described in the Methods. The bound complex was separated from residual conjugate by centrifugation. Confocal images of
(A) binding buﬀer containing AF488-annexin-V conjugate without MVs and (B) AF488-annexin-V-bound MVs without stimulation or (C) after
stimulation with 1 mM ATP. The scale bar (16 μm) in Panel C applies to images A−C. Panels D−F are higher resolution images of multiple selected
regions on slides containing MVs from ATP-stimulated microglia.

precursor protein (APP).18−21 The additional two hydrophobic
amino acid residues on Aβ42 give the peptide a signiﬁcantly
increased propensity for aggregation22 and a key role in AD
etiology.23
Recent investigations have strengthened the likelihood that
both exosomes and MVs have a role in AD. Exosomes isolated
from the cerebrospinal ﬂuid (CSF) of AD patients and the
plasma of two AD mouse models contained low levels of Aβ
but with an increased Aβ42/Aβ40 ratio.24 MVs were elevated in
CSF of AD patients and correlated with greater neurodegeneration.25 These studies have built on others implicating
EVs in a variety of processes that underlie multiple neurodegenerative diseases.1 One source of MVs may be microglia,

cargo-holding particles and multiple disease states, including
AD, is becoming more evident.
AD pathology is highlighted by the abnormal aggregation
and accumulation of amyloid-β peptide (Aβ) observed as
plaques in the brain parenchyma and intraneuronal neuroﬁbrillary tangles comprised of tau-protein.14 The aberrant
protein accumulation creates a toxic environment in selected
areas of the brain, triggering neuronal loss and progressive
dementia. Adding to the pathological complexities is the
potential involvement of soluble oligomeric species of both Aβ
and tau15,16 and accompanying neuroinﬂammation in aﬀected
brain regions.17 The predominant forms of Aβ are Aβ40 and
Aβ42. Both are produced by proteolytic cleavage of the amyloid
1417
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Figure 3. Size analysis of microglia-derived MVs by DLS. Diﬀusion coeﬃcients were obtained and converted to hydrodynamic radius (RH) as
described in the Methods for (A) MVs obtained from BV-2 microglia without stimulation and (B) MVs obtained from BV-2 microglia after
stimulation with 1 mM ATP. Regularized histograms of % intensity (i.e., prevalence) versus RH are presented. Mean RH values for the representative
histograms were (A) 123 and (B) 146 nm. Panel C represents DLS histograms for six separate MV isolations from BV-2 microglia. Corresponding
colors are MV prep #1 (red), MV prep #2 (orange), MV prep #3 (yellow), MV prep #4 (green), MV prep #5 (teal), and MV prep #6 (dark blue).
The mean intensity-weighted RH value of the predominant population (70−300 nm) over all 6 preparations was 137 ± 13 nm (standard deviation)
or 274 ± 27 nm in diameter.

alone, which is consistent with a previous report.11 Although
much less in amount, MVs were shed from microglia without
ATP stimulus, suggesting a constitutive shedding process. MV
protein content was determined by bicinchoninic acid (BCA)
protein assay, which indicated that MVs shed from ATPstimulated microglia had a greater protein content compared to
that of aCSF-treated microglia (Figure 1B). The protein
concentration determination may be reﬂective of a greater
number of MVs or higher protein within each MV or both.
Externalized phosphatidylserine (PS) is a marker of apoptotic
bodies and MVs. The 2000g centrifugation step in the
preparation of MVs removed apoptotic bodies and allowed
detection of MVs by annexin-V binding. MVs incubated with
AlexaFluor 488-labeled annexin-V (AF-annexin-V) were
adsorbed to a microscope slide and imaged by confocal
microscopy. AF-annexin-V binding buﬀer alone did not adsorb
to the slide or display any ﬂuorescence (Figure 2A), while MVs
bound to AF-annexin-V were observed in unstimulated
microglia (Figure 2B). This ﬁnding suggested that MVs are
continually produced and shed from microglia without
stimulation. Treatment of the microglia with 1 mM ATP
yielded signiﬁcantly more MVs as evidenced by the increased
clusters and overall amount of AF-annexin-V ﬂuorescence
(Figure 2C).
Morphology and Size of Microglial Microvesicles.
Morphological and initial size information was obtained from
confocal images of AF-annexin-V-labeled MVs at a higher
magniﬁcation (Figures 2D−F). Ring-like (presumably spherical
in 3 dimensions) structures with circumferential ﬂuorescence
were observed consistent with AF-annexin-V binding to PS on
the MV surface. Scale bars for the images allowed a size
estimation of <5 μm. To obtain a more rigorous determination
of MV size, dynamic light scattering (DLS) was utilized. DLS is
a sensitive technique that relies on light scattering from the
particle detected at a 90° angle to measure diﬀusion coeﬃcients
(DT) for particle populations. DT is converted to hydrodynamic
radius (RH), and the eﬀective range is 1−1000 nm for the
instrument used in these studies (DynaPro Titan, Wyatt
Technology). Mean RH was obtained, and size histograms were
generated to deﬁne the MV distribution. DLS measurements
from a representative MV preparation yielded a mean RH of
136 ± 4 (standard error measurement, SEM) for unstimulated

which are extensively involved in AD neuroinﬂammation. The
mechanisms by which MVs impact AD are not fully clear but
may involve direct or indirect eﬀects on the amyloid precursor
protein (APP), amyloid-β (Aβ), tau, or other key molecules in
AD etiology. One type of reported interaction between Aβ and
microglial-derived MVs resulted in the conversion of ﬁbrillar
Aβ to a more soluble and neurotoxic form.26 Despite the
increasing attention to interactions between EVs and
aggregation-prone proteins, there are some contrasts between
diﬀerent investigations and types of EVs.27 The previous
ﬁndings to this point suggest a mechanism whereby microglial
MVs may interact with Aβ, modulate Aβ, and potentially serve
as an extracellular spreading mechanism for a particular form of
Aβ. In the current study, MVs shed from microglia were
characterized by multiple microscopic and spectroscopic
methods and investigated for their ability to interact with,
and traﬃc, Aβ. The ﬁndings herein provide further evidence of
a direct role for MVs in the underlying biochemistry of AD.

2. RESULTS AND DISCUSSION
Generation and Isolation of Microglia-Derived Microvesicles. Isolation of cell-secreted MVs can be elusive and
inconsistent. In an eﬀort to improve this process, multiple
microscopy and spectroscopy methodologies were utilized to
characterize MVs released from microglia cells (Figure 1A).
Greater MV yields were achieved when large conﬂuent 150 cm2
ﬂasks of BV-2 microglia were used. BV-2 microglia were treated
with artiﬁcial cerebrospinal ﬂuid (aCSF) containing 15 mM
NaHCO3, 1 mM Na2HPO4, 130 mM NaCl, and 3 mM KCl,
pH 7.8 alone or aCSF containing 1 mM ATP for 10 min. The
conditioned medium was collected from each ﬂask and
centrifuged at 2000g for 20 min to remove loose cells and
cell debris. This was a critical step to separate MVs from
apoptotic bodies, which display a few characteristics that are
similar to MVs such as protein cargo and externalized
phosphatidylserine. The supernatant containing MVs was
subjected to higher speed centrifugation (12 200−15 000g for
40 min) to isolate MVs in the resulting pellet. Following
multiple washes, the MV pellets were reconstituted in aCSF for
further characterization. It was apparent by several diﬀerent
measures described below that MVs shed by microglia
increased substantially after exposure to ATP relative to buﬀer
1418
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Figure 4. Electron microscopy of resin-embedded microvesicles. MVs were ﬁxed, stained with uranyl acetate, dehydrated sequentially in increasing
percentages of ethanol, and embedded in low viscosity resin as described in the Methods. After hardening, thin slices (80 nm) were prepared by
microtome and TEM images obtained for MVs isolated from (A) unstimulated (aCSF treated) BV-2 microglia and (B) ATP-stimulated BV-2
microglia.

microglia and 129 ± 1 nm for ATP-stimulated microglia (n =
25−30 acquisitions each). Regularized histograms, which
separate distinct populations, produced mean histogram RH
values for MVs of 123 and 146 nm for unstimulated and ATPstimulated microglia, respectively (Figures 3A and B).
Measurements taken and averaged from multiple ATPstimulated microglial MV preparations resulted in a regularized
histogram RH of 137 ± 13 nm for n = 6 preparations with an
overall range of 80−250 nm (Figure 3C). A relatively minor
population of smaller vesicles (25−35 nm) was also detected.
Conversion of hydrodynamic radius to diameter placed the
microglia MVs in this study in a size range (160−500 nm, mean
274 nm) consistent with previous descriptions of MVs in the
100−1000 nm range.2 Even though MVs shed from ATPtreated microglia and MVs from unstimulated microglia were
similar in size, light scattering intensity was substantially
increased (4.6 fold) for the former compared to the latter (data
not shown). This again pointed to an increase in MV numbers
after stimulation of microglia with ATP.
To obtain higher-resolution morphological information, thinsliced resin-embedded MV samples were examined with
transmission electron microscopy (TEM). Images were taken
of embedded MVs shed from both unstimulated and ATPstimulated microglia. The vesicular architecture was clearly
evident for the MVs, and the size estimation was consistent
with the DLS measurements (Figures 4A and B). The surface
exterior was rougher for the MVs shed from ATP-stimulated
microglia (Figure 4B) compared to those shed from
unstimulated microglia (Figure 4A). The rougher surface
architecture may be related to the greater protein content
measured in MVs shed from ATP-stimulated microglia.
Tracking of Microvesicles with NBD C6−HPC. MVs shed
from microglia were detected by incorporation of NBD-labeled
hexadecanoyl-phosphocholine (NBD C6−HPC) into MV
membranes and subsequent ﬂuorescence measurements.
Insertion of NBD C6−HPC into MVs resulted in a blue shift
in NBD ﬂuorescence (λmax) from 552 to 544 nm due to the
hydrophobic membrane environment (Figure 5A). NBD C6−
HPC was very useful in tracking MVs through the isolation

Figure 5. Fluorescent tracking of microvesicles by NBD C6−HPC
insertion. As described in the Methods, MV suspensions were
incubated with NBD C6−HPC (10 μM) and then isolated by
centrifugation. The MV pellet was washed 3× with aCSF buﬀer and
the pellet reconstituted at the same original volume. (A) Insertion of
NBD C6−HPC into the MV membrane caused a blue shift in the
NBD ﬂuorescence emission (λmax). Data are the average ± standard
error [***p < 0.001] for n = 16 total NBD ﬂuorescence measurements
over 2 separate MV isolations. (B) NBD ﬂuorescence was measured in
the initial centrifugation supernatant containing residual NBD C6−
HPC, the three wash steps, and the reconstituted MV pellet.
Fluorescence measurements from parallel MV isolations from
unstimulated BV-2 microglia (black bars) and ATP-stimulated BV-2
microglia (gray bars) are shown. Data are the average ± standard error
(**p < 0.01) for n = 4 separate samples from each MV isolation.

process by ﬂuorescence when needed. Inclusion of 10 μM NBD
C6−HPC in the supernatant after the 2000g centrifugation step
(see Figure 1A) facilitated insertion into, and labeling of, MVs.
Reconstitution of the MV pellet, after several rounds of
centrifugation at 12 200−15 000g and washing after each spin
to remove residual NBD C6−HPC, demonstrated the sustained
incorporation of the ﬂuorophore in the MVs (Figure 5B). The
NBD C6−HPC incorporation studies were in agreement with
the annexin-V binding and DLS results as all three showed
greater MV numbers shed from microglia treated with ATP
(Figure 5B).
Interaction of Microvesicles With Aβ. Recent ﬁndings
indicated an interaction between MVs with Aβ,26 which may
potentially be important in the spreading or accretion of
extracellular Aβ. In the current study, in vitro binding
experiments were conducted to determine if microglial MVs
1419
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have a diﬀerent aﬃnity for soluble Aβ42 monomers and Aβ42
protoﬁbrils. Equal amounts of isolated MVs shed from ATPstimulated microglia were incubated with NBD C6−HPC and
either SEC-isolated Aβ42 monomers or protoﬁbrils. For
replicate experiments, protein concentration was used to
equalize MVs. Subsequent centrifugation, ﬁve rounds of
washing, and reconstitution of the MV pellet removed all
residual NBD C6−HPC and isolated the NBD-labeled MVs
(Figure 6A). MV numbers were similar in both Aβ42 monomer

Figure 7. MVs inhibit Aβ42 monomer aggregation. SEC-puriﬁed Aβ42
monomers (20 μM) were incubated quiescently at 4 °C with or
without MVs (105 μg/mL, experiment #1, panel A; 100 μg/mL,
experiment #2, panel B) obtained from ATP-stimulated BV-2
microglia. The two panels depict separate experiments involving
diﬀerent MV isolations and Aβ42 monomer puriﬁcations. ThT
ﬂuorescence was measured as described in the Methods. (A) Triplicate
parallel Aβ42 monomer solutions with or without MVs are shown and
plotted as a comparison of the two conditions when maximal
aggregation by ThT ﬂuorescence was reached. This is written as %
max agg on the y-axis. (B) Time course of Aβ42 monomer aggregation
with or without MVs measured by ThT ﬂuorescence. Each data point
represents the average ± standard error for n = 3 samples for each
condition.

Figure 6. Aβ42 protoﬁbrils interact strongly in vitro with microglialderived MVs. MVs were isolated from ATP-stimulated BV-2 microglia
as described earlier. SEC-isolated Aβ42 protoﬁbrils or monomers (5
μM) were incubated with MVs (87 μg/mL, experiment #1; 125 μg/
mL, experiment #2) in the presence of 10 μM NBD C6−HPC. MV-Aβ
binding complexes were isolated by centrifugation for 40 min at
12 200g. Both protoﬁbrils and monomers are soluble under these
centrifugation conditions and do not sediment. MV pellets were
washed 5× with aCSF buﬀer and reconstituted. (A) NBD ﬂuorescence
was measured for the ﬁfth and ﬁnal wash (W5) and the MV pellet
from each protoﬁbril (PF) and monomer (Mon) binding reaction.
The ﬂuorescence data is from 1 of 2 independent MV-Aβ interaction
experiments. (B) An Aβ42-selective ELISA was conducted on samples
from the 2 independent MV-Aβ interaction experiments. The ELISA
data are the average ± standard error for n = 8 total measurements of
each binding reaction (4 from each experiment) (***p < 0.001 or NS,
not signiﬁcant). Concentrations were determined from an Aβ42
standard curve.

extended in the presence of MVs, and the maximum ThT
ﬂuorescence reached a notably lower level (Figure 7B).
Microglia Traﬃcking of Aβ into MVs. Recent ﬁndings
from Verderio and colleagues indicated that exogenous Aβ
added to microglia emerges in shed MVs.26 It is likely that Aβ
structure and aggregation state have an inﬂuence on traﬃcking
via microglia into MVs. We previously showed that Aβ42
protoﬁbrils, but not Aβ42 monomers, are rapidly and
extensively internalized into primary murine microglia.28
Therefore, experiments were conducted to determine whether
internalized Aβ42 protoﬁbrils may be traﬃcked into MVs
destined for release from microglia. NBD C6−HPC insertion
studies and DLS analysis were used to verify MV release from
primary microglia (data not shown). Primary microglia were
incubated with SEC-isolated Aβ42 protoﬁbrils for 0.5 h to allow
time for Aβ internalization. We previously utilized multiple
strategies to monitor microglial uptake of Aβ, including
confocal microscopy, ﬂuorescence spectroscopy, and immunodot blot.28 The latter procedure was used in these studies to
verify internalization of Aβ42 protoﬁbrils. Following the cell
incubation, the medium was removed, and the cells washed
extensively (5×) prior to a 30 min stimulation with 2′(3′)-O(4-benzoylbenzoyl)adenosine 5′-triphosphate triethylammonium salt (BzATP). BzATP is an eﬀective agonist for P2X7
purinergic receptors29 and was used with primary microglia
based on its eﬀectiveness in eliciting MV release as previously
reported.30 MVs were collected, and the microglia were washed
6× before lysing of the cells and acquisition of the intracellular
lysate.
Immuno-dot blot analysis was conducted using a previously
characterized protoﬁbril-selective antibody, AbSL.31 Probing of
the wash steps before and after ATP stimulation demonstrated
the removal of residual and cell surface-attached Aβ42
protoﬁbrils from the microglia (Figure 8A). Of note was the
absence of Aβ42 in the acid wash (0.5 M NaCl/0.2 M acetic
acid) conﬁrming that the microglia cell surface was free of
Aβ42. This is consistent with our previous work demonstrating
rapid internalization and very little cell-surface accumulation of
Aβ42 protoﬁbrils under short (≤1 h) incubation times.28 The

or protoﬁbril reactions as measured by NBD ﬂuorescence.
However, when Aβ42 was measured by Aβ42-speciﬁc ELISA in
the reconstituted MV pellets, it was clear that the MVs
interacted with Aβ42 protoﬁbrils much more strongly
compared to monomers (Figure 6B). Furthermore, the
numerous wash steps reduced the residual or free Aβ42 in
the MV pellet fractions. The ﬁndings indicated a selective
interaction with a soluble aggregated protoﬁbrillar form of Aβ.
Impact of Microglial Microvesicles on Aβ Aggregation. Despite just a minor interaction observed with Aβ42
monomers (shown in Figure 6B), it was of interest to examine
the eﬀect of microglial-derived MVs on monomer aggregation.
SEC-puriﬁed Aβ42 monomers were incubated over time in the
absence or presence of MVs, and the reactions were monitored
by thioﬂavin T (ThT) binding and ﬂuorescence. In the ﬁrst set
of experiments, time points were taken initially and then
periodically during all reactions. As expected, a lag phase was
observed for all reactions followed by a growth phase. When
the Aβ42 (−MVs) control reactions reached maximum ThT
ﬂuorescence, comparisons to Aβ42 (+MVs) were made. MVs
signiﬁcantly suppressed Aβ42 monomer aggregation in all
reactions (Figure 7A). The fact that the control Aβ42 reactions
peaked at slightly diﬀerent times prompted the depiction of the
ﬁndings as separate reactions as shown. Subsequent experiments conﬁrmed the inhibitory eﬀect of MVs on Aβ42
monomer aggregation. The Aβ42 aggregation lag phase was
1420
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3. CONCLUSIONS
The ﬁndings from this study highlight the physical features and
properties of microglia-derived MVs. The physical characterization helped provide a foundation for understanding
interactions between MVs and Aβ. The MVs in the current
investigation were similar in size and morphology to several
previous studies in which MVs were isolated from astrocytes,
microglia/macrophages, mast cells, erythroleukemia cells, and
BV-2 murine microglia and analyzed by TEM.13,32,33 All three
studies used diﬀerential centrifugation to separate apoptotic
bodies, MVs, and exosomes. The centrifugation forces were
slightly diﬀerent but resulted in three pelleted fractions, 1200g,
20 min (P2); 10 000g, 30 min (P3); 110 000g, 60 min (P4)13,32
and 2000g, 20 min (apoptotic bodies); 12 200g, 40 min (MVs);
120 000g, 70 min (exosomes).33 The P3 pellet in Bianco et al.
and Verderio et al. and MV pellet in Crescitelli et al.
corresponded to the microglial-derived MVs in this study
both in morphology and methodology. Notably, we found that
MVs were constitutively released from microglia, although ATP
greatly stimulated MV numbers and protein content. The use
of ﬂuorescently labeled annexin-V and confocal microscopy also
resulted in images of MV architecture that were consistent with
previously published reports. MacKenzie et al. observed a halo
of MVs blebbing from the surface of HEK cells using FITCconjugated annexin-V.34 Bianco et al. also used FITC-annexinV to show surface MV blebs after ATP stimulation of N9
microglia.11 Our ﬁndings and methodology were similar to
additional studies, which characterized isolated MVs directly
with ﬂuorescently labeled annexin-V and microscopy.13,32
However, the MV images presented in the current study
further revealed the ring-like pattern that would be expected of
spherical vesicles.
In vitro binding studies showed that MVs interacted strongly
with soluble Aβ42 protoﬁbrils compared to Aβ42 monomers.
We have repeatedly observed that protoﬁbrils possess particular
surface properties that are highly amenable to cell interaction,35
cell stimulation,36−38 and cell uptake.28 The interaction of
protoﬁbrils with microglia-derived MVs ﬁt this same pattern.
Joshi et al. found that MVs had a functional interaction with
insoluble Aβ42 ﬁbrils resulting in conversion of the ﬁbrils to
smaller soluble more toxic forms.26 A similar type of conversion
was previously observed after incubation of Aβ42 ﬁbrils with
various 200 nm lipid-containing liposomes, resulting in more
neurotoxic protoﬁbrils.39 This may be a mechanism similar to
that observed by An et al., whereby exosomes infused into
anesthetized rats blocked Aβ-induced synaptotoxicity by
sequestration of Aβ assemblies.40
The determination that microglia-derived MVs inhibited
Aβ42 monomer aggregation has not been demonstrated before.
This result contrasts with two separate studies wherein
exosomes stimulated Aβ aggregation. Acceleration of Aβ40
and Aβ42 aggregation was observed in the presence of
exosomes isolated from PC-12, N2a, and primary neurons.41,42
A recent study conﬁrmed the stimulation of Aβ42 aggregation
by N2a-derived exosomes and demonstrated a role for the
prion protein in the process.43 The overall ﬁndings on the
impact of EVs on Aβ aggregation reveal marked diﬀerences
between exosomes and MVs. The diﬀerential eﬀects may be
due to variations in size, cargo, and surface-exposed
biomolecules for the two primary types of EVs. Whether
microglia-derived MVs have a neuroprotective, neurodegenerative, or benign inﬂuence on AD requires further investigation.

Figure 8. Aβ42 protoﬁbrils are internalized by microglia and traﬃcked
into shed MVs. Primary murine microglia were exposed to Aβ42
protoﬁbrils (5 μM) for 0.5 h as described in the microglia traﬃcking
section of the Methods. (A) Dot blot analysis with an Aβ42
protoﬁbril-selective antibody (AbSL) of the medium and PBS wash
steps following microglia exposure to Aβ42 protoﬁbrils prior to (Aβ:
med, W1−5) and after treatment with 100 μM BzATP (ATP: W1−2,
acid, W4−6) along the microglia cell lysate. (B) MVs were collected
following stimulation of the primary microglia in Panel A with BzATP
in aCSF. ELISA measurements were carried out on reconstituted MVs
isolated by centrifugation (pellet) and the ﬁfth wash (W5) after 5 wash
steps with aCSF. Data bars represents the average ± standard error for
n = 12 total measurements obtained from three independent
experiments (***p < 0.001). Actual Aβ42 concentrations averaged
173 pg/mL over the 3 experiments. The data is presented as % MV
pellet to accommodate variances in actual concentrations between
independent experiments.

presence of Aβ42 in the lysate veriﬁed microglial internalization
of Aβ42 protoﬁbrils. The collected MVs were pelleted by
centrifugation and washed extensively (5×). The reconstituted
MV pellets were analyzed with an Aβ42-speciﬁc ELISA and
compared with the last wash steps (W5). Figure 8A is
representative of three separate experiments. Figure 8B is the
average of those same experiments, which clearly demonstrated
the presence of Aβ42 in the MV pellets. DLS measurements of
MVs shed from primary microglia indicated that the MV size
increased after exposure of the microglia to Aβ42 protoﬁbrils
(Figure 9). In three separate experiments, MVs collected from

Figure 9. MVs that are traﬃcking Aβ42 protoﬁbrils are larger in size.
MVs obtained from primary microglia without (MVs − Aβ) or with a
30 min exposure to Aβ42 protoﬁbrils (MVs + Aβ) were analyzed by
DLS. After removal of the medium and extensive washing with sterile
PBS to remove surface Aβ, MV release was stimulated by treatment of
microglia with 100 μM BzATP and isolated as described in the
Methods. Mean RH values were obtained for each MV preparation,
converted to diameters, and presented as the average ± standard error
(*p < 0.05) for n = 3 separate preparations for each condition.

microglia without Aβ treatment averaged 449 nm in diameter,
while MVs released from microglia after Aβ treatment averaged
1142 nm in diameter (Figure 9). The ﬁndings indicated that
exogenous Aβ42 protoﬁbrils were internalized by microglia and
then traﬃcked into MVs destined for shedding.
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NaHCO3, 1 mM Na2HPO4, 130 mM NaCl, 3 mM KCl, pH 7.8) or 4
mL aCSF containing 1 mM ATP. The conditioned aCSF was removed
from the microglia and centrifuged at 2000g for 20 min. The
supernatant was removed and centrifuged at 12 200−15 000g for 40
min. The resulting MV pellets were washed extensively with, and
reconstituted in, aCSF and stored at 4 °C. MVs were obtained from
primary microglia by the same methods except 75 cm2 ﬂasks were used
and treated with 2 mL aCSF containing 100 μM BzATP.
4.3. Protein Concentration Determination. Measurement of
protein concentration in microvesicles was carried out as described by
Verderio and colleagues.32 A bicinchoninic acid (BCA) assay (Pierce)
was carried out in a 96-well microplate. Ten microliters from a bovine
serum albumin (BSA) standard curve (15−2000 μg/mL) and four MV
replicates were mixed with a 100 μL solution containing 50 parts
Reagent A and 1 part Reagent B. The wells were incubated for 30 min
in a water bath at 37 °C and then allowed to cool to ambient
temperature. Absorbance was measured at 562 nm with a Molecular
Devices SpectraMax 340 platereader and protein concentration
determined from the standard curve.
4.4. Dynamic Light Scattering. Hydrodynamic radius (RH)
measurements were made at ambient temperature with a DynaPro
Titan instrument (Wyatt Technology, Santa Barbara, CA). Samples
(35 μL) were placed directly into a quartz cuvette, and light scattering
intensity was collected at a 90° angle using a 5-s acquisition time.
Particle diﬀusion coeﬃcients were calculated from autocorrelated light
intensity data (>25 acquisitions) and converted to RH with the
Stokes−Einstein equation. Mean RH values were obtained with
Dynamics software (version 6.12.03). Histograms were generated by
Dynamics data regularization, and intensity-weighted mean RH values
were derived from the regularized histograms of percent intensity vs
RH .
4.5. Annexin-V Binding Assay. MV pellets obtained from buﬀeror ATP-treated BV-2 microglia were reconstituted in 0.5 mL binding
buﬀer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4).
AlexaFluor 488 (AF488)-annexin-V conjugate (25 μL) was added to
the MVs with gentle mixing and samples were incubated at 25 °C for
15 min. The solution was then centrifuged at 12 200g for 40 min to
separate the MV pellets from residual conjugate. The supernatant was
removed, and the pellet was resuspended in 0.2 mL binding buﬀer.
Fifty microliters of the AF488-annexin-V-labeled MV solutions was
placed on a microscope slide, and a coverslip was carefully applied.
Confocal microscopy images were obtained with a Zeiss LSM 700
confocal microscope at an excitation wavelength of 488 nm at 20 or
40× magniﬁcation. ZEN 2009 software was used for imaging and
analysis.
4.6. Resin-Embedded Transmission Electron Microscopy
(TEM). Embedding of isolated MVs was carried out using a modiﬁed
version of previously published work.33 All resin-embedding steps were
conducted at 25 °C with a 0.2 mL phosphate-buﬀered saline (PBS)
wash after each step. MVs obtained from BV-2 microglia treated with
either aCSF buﬀer or aCSF containing 1 mM ATP were centrifuged at
12 200g for 40 min and 17 000g for 10 min. MV pellets were washed,
ﬁxed in place using 4% paraformaldehyde in 10 mM phosphate buﬀer,
and incubated for 1 h. After removal of the solution, the pellet was
washed, and a 1% osmium tetroxide (OsO4) solution (0.2 mL) in 10
mM phosphate buﬀer was applied to the pellet and incubated for 30
min. After removal of the OsO4 and washing, an ethanol dehydration
series was performed using 0.2 mL of 50, 70, 90, and 100% ethanol
solutions successively. The 50% solution contained 2% uranyl acetate.
The pellet was incubated 30 min for each dehydration step following
removal and addition of the previous and next ethanol solution.
Embedding resin (Low Viscosity Embedding Media Spurr’s Kit,
Electron Microscopy Sciences, Hatﬁeld, PA) was added to the MV
pellets, which were then solidiﬁed in an oven at 80 °C for 12 h. Resinembedded samples were sliced with an UltracutS microtome (Leica
Reichert, Buﬀalo Grove, IL), applied to a 200-mesh Formvar-coated
copper grid (Ted Pella, Inc.), washed 3× with water, and visualized
with a Philips EM430 transmission scope operated at 300 KeV.
4.7. NBD C6−HPC Labeling of Microvesicles. Following
collection of MVs in the conditioned aCSF from microglia and

The ability of phagocytic cells such as microglia to internalize
Aβ is well-established.44 The appearance of previously
internalized proteins with released EVs is a relatively new
phenomenon. Our laboratory recently demonstrated the rapid
and extensive internalization of Aβ42 protoﬁbrils by microglia.28 In the current study, we now found that Aβ42
protoﬁbrils that have been internalized by primary microglia
are rapidly traﬃcked outside of the cell via shed MVs. Verderio
and colleagues observed a similar traﬃcking process in which
Aβ-treated microglia released MVs that were associated with
Aβ.26 Furthermore, Söllvander et al. showed internalization of
Aβ protoﬁbrils by astrocytes and subsequent release of
astrocytic MVs containing N-truncated Aβ.45 In our paradigm,
extensive and stringent microglial cell washing was done prior
to measurement of MV-associated Aβ42. This procedure
removed cell surface-associated Aβ42 and strengthened our
interpretation that the Aβ was encapsulated within the MV.
Mattson and coworkers recently reported on the isolation of
EVs (likely a mixture of exosomes and MVs) from AD patient
CSF and plasma, the plasma of two AD mouse models, and
medium from neural cells expressing familial AD presenilin 1
mutations.24 The isolated EVs contained a relatively low
amount of Aβ but had an increased Aβ42/Aβ40 ratio, with the
majority of Aβ located on the EV surface.
EVs, including MVs and exosomes, are an emerging area of
research and may have integral roles in many physiological and
disease-related processes. Accumulating research appears to link
MVs to particular pathways that are susceptible to, or
contribute to, AD. Many questions are still unanswered with
respect to external interactions between MVs and aggregationprone proteins, fate of MVs involved in traﬃcking these
proteins, and the impact on neuroinﬂammation or neurotoxicity by MVs in consort with protein aggregates.

4. METHODS
4.1. Cell Culture. BV-2 murine microglia cells were cultured as
previously described.38 Cells were maintained in 150 cm2 ﬂasks
(Corning) in Dulbecco’s modiﬁed Eagle’s medium (DMEM, 4.5 g/L
glucose) (Hyclone) containing 50 U/mL penicillin, 50 μg/mL
streptomycin, 50 μM β-mercaptoethanol, and 5% heat-inactivated
fetal bovine serum (FBS, Hyclone). Acquisition and culture of primary
murine microglia have been previously described.38,46 C57BL/6 mice
(Harlan Laboratories) were housed in the University of Missouri-St.
Louis Animal Facility. Primary microglia were obtained from 3 to 4
day old newborn mouse pups after euthanizing with inhaled isoﬂurane
(Henry Schein, Melville, NY). Brains were separated and meninges
removed under sterile conditions. The brain tissue was minced and
further dissociated in 0.5% trypsin (Hyclone) at 37 °C. Tissue was
resuspended in complete DMEM containing 10% fetal FBS, 4 mM Lglutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 0.25 μg/
mL amphotericin-B (Fisher Scientiﬁc), OPI medium supplement
(oxaloacetate, pyruvate, insulin, Sigma-Aldrich), and 0.5 ng/mL
recombinant mouse granulocyte macrophage colony-stimulating factor
(GM-CSF) (Invitrogen). The cell suspension was triturated, ﬁltered
through a 70 μm cell strainer, and centrifuged at 200g for 5 min at 25
°C. The pellet was resuspended in complete medium, seeded into 150
cm2 ﬂasks (Corning), and the mixed glial cells were incubated at 37 °C
in 5% CO2 for 1−2 weeks. Microglia were selectively harvested from
the adherent astrocyte layer by shaking ﬂasks for 5 h at 250 rpm on a
19 mm orbit rotary shaker (MidSci, St. Louis) at 37 °C in 5% CO2 and
collection of the medium.
4.2. Stimulation and Isolation of Microvesicles. MVs were
obtained from both BV-2 and primary murine microglia using a
modiﬁed version of previously published protocols.33,13 For MVs from
BV-2 cells, conﬂuent microglia in 150 cm2 ﬂasks were treated for 10
min with either 4 mL artiﬁcial cerebrospinal ﬂuid (aCSF, 15 mM
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centrifugation at 2000g, 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine (NBD
C6−HPC, Life Technologies) was added to the supernatant of each
tube at a ﬁnal concentration of 10 μM and incubated for 15 min at 25
°C. Tubes were then centrifuged at 12 200−15 000g for 40 min to
isolate MVs in the pellet fraction. The pellet was washed multiple
times in aCSF with a 12 200−15 000g 40 min spin after each wash.
The MV pellets were reconstituted in aCSF, and the saved
supernatants from the wash steps were analyzed with a Cary Eclipse
ﬂuorescence spectrophotometer. Emission scans of 500−600 nm were
obtained with an excitation wavelength of 485 nm for the NBD
ﬂuorophore. The resulting curves were integrated from 520 to 580 nm
to produce relative ﬂuorescence units (RFU).
4.8. Preparation of Aβ Peptide. Aβ42 was obtained from The
ERI Amyloid Laboratory, LLC (Oxford, CT) in lyophilized form and
dissolved in 100% hexaﬂuoroisopropanol (HFIP) (Sigma-Aldrich, St.
Louis) to yield a 1 mM Aβ solution. The solution was separated into
aliquots in sterile microcentrifuge tubes and evaporated uncovered
overnight in a fume hood. The following day, the aliquots were
vacuum-centrifuged to remove any residual HFIP and stored in
desiccant at −20 °C. Aβ42 monomers were obtained by reconstitution
of stored Aβ42 aliquots (1 mg) in a 6 M guanidine hydrochloride
(GuHCl)/10 mM NH4OH solution and centrifugation of the solution
at 17 000g for 10 min with a Beckman-Coulter Microfuge 18 prior to
chromatographic separation of the supernatant. Aβ42 protoﬁbrils were
prepared as previously described38 by dissolving lyophilized Aβ42 (1
mg) in 50 mM NaOH to yield a 2.5 mM Aβ solution. The solution
was then diluted to 250 μM Aβ in preﬁltered (0.22 μm) aCSF,
incubated for 15−30 min, centrifuged at 17 000g for 10 min, and the
supernatant was separated chromatographically.
4.9. Size Exclusion Chromatography and Aβ42 Aggregation.
Supernatants of Aβ42 preparations were fractionated on a Superdex 75
HR 10/30 column (GE Healthcare) using an AKTA FPLC system
(GE Healthcare) as previously described.47 Following loading of the
sample, Aβ42 monomers or protoﬁbrils were eluted at 0.5 mL min−1
in aCSF, and 0.5 mL fractions were collected and immediately placed
on ice. Aβ42 concentrations were determined by in-line UV
absorbance using an extinction coeﬃcient of 1450 cm−1 M−1 at 280
nm. Aggregation of Aβ42 monomers (ﬁnal concentration 40 μM) was
carried out in sealed siliconized tubes at 4 °C without agitation.
4.10. ELISA. Aβ42 concentrations were determined with a
Quantikine Aβ(1−42)-speciﬁc ELISA (R&D Systems) according to
manufacturer protocols. Standard curves were prepared by reconstitution of dry Aβ42 peptide provided with the kit in a concentration
range of 8−500 pg/mL.
4.11. Thioﬂavin T Fluorescence. Aβ solutions were assessed by
ThT ﬂuorescence as described previously.48 Aβ aliquots were diluted
to 5 μM in aCSF pH 7.8 containing 5 μM ThT. Fluorescence emission
scans (460−520 nm) were acquired on a Cary Eclipse ﬂuorescence
spectrophotometer using an excitation wavelength of 450 nm and
integrated from 470 to 500 nm to obtain ThT relative ﬂuorescence
values. Buﬀer controls did not show any signiﬁcant ThT ﬂuorescence
in the absence of Aβ. All ThT ﬂuorescence values are reported in
relative ﬂuorescence units.
4.12. Microglia Traﬃcking Assay. Primary microglia were
harvested as described above in the Cell Culture section and reseeded
into 75 cm2 ﬂasks. After the microglia were allowed to adhere
overnight, the growth medium was replaced with assay medium
(growth medium without FBS and GM-CSF). Microglia were then
treated with SEC-isolated Aβ42 protoﬁbrils (5 μM) for 0.5 h followed
by removal of the assay medium and washing of the microglia 3−5
times with sterile PBS. All cell treatment steps and washes were
collected for further analysis. Microglia were then treated with 2 mL
aCSF containing 100 μM BzATP for 30 min at 37 °C in 5% CO2. The
conditioned solution containing MVs was set aside brieﬂy while the
adherent microglia were washed 3−6 additional times, including one
acid wash consisting of 0.5 M NaCl and 0.2 M acetic acid. After the
ﬁnal wash, the microglia were lysed under gentle rotation for 15 min
with 1 mL radioimmunoprecipitation assay (RIPA) buﬀer containing
150 mM NaCl, 20 mM Tris, 1 mM ethylenediamine tetraacetic acid

(EDTA), 1% Triton X-100, 1% deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), and a 10× dilution of protease inhibitor cocktail
(Sigma-Aldrich). The lysate was transferred to a sterile round-bottom
tube and stored at −20 °C awaiting further analysis. MVs were
pelleted by centrifugation as described above and washed 5× with
aCSF with centrifugation steps in between each wash. MV pellets were
then reconstituted in aCSF for Aβ42 concentration determination and
size analysis.
4.13. Dot Blot. Dot blot analysis was carried out as previously
described.28 Brieﬂy, microglial cell lysates, assay medium, and wash
steps (1.7 μL) from the traﬃcking studies were spotted on a
nitrocellulose membrane and blocked with PBS containing 0.1%
Tween 20 and 5% milk for 1 h. All steps in the assay were done at 25
°C on a platform rotary shaker with gentle rotation. Wash steps
involved 3 separate 5 min washes with PBS containing 0.2% Tween 20,
pH 7.4. After blocking, the membrane was washed and incubated for 1
h each with an Aβ protoﬁbril-selective antibody, AbSL31 and an
antirabbit IgG-horseradish peroxidase (HRP) with a wash step in
between. The primary antibody (1:5000) and secondary antibody
(1:1000) were diluted in PBS containing 1% milk and 0.1% Tween 20.
After washing, the membrane was soaked in enhanced chemiluminescence substrate solution (Pierce), washed for 1 min, dried, and
exposed to ﬁlm for 1 min in an autoradiography cassette. The ﬁlm was
developed, ﬁxed, washed in water, and dried for image scanning.
4.14. Statistical Analysis. Two-tailed paired Student t tests were
performed when applicable in Microsoft Excel 2016 to determine the
conﬁdence limit at which two measurements were statistically
diﬀerent. Analysis was applied to each data set, and p-values (*p <
0.05, **p < 0.01, ***p < 0.001) were obtained and reported in the
ﬁgure legends.
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